The global heart attack diagnostics market size is estimated to expand at a considerable CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to rising prevalence of heart disease cases, increasing research & government initiatives, and increasing health expenditure.
Heart attack, also known as Myocardial Infarction (MI), is a type of heart disease that generally occurred when heart stops its normal function. Without proper medications or medical guidelines, patients with heart diseases have a high risk of heart attack or cardiac arrest that can cause death. The pathophysiology of heart attack includes tissue necrosis of myocardium layer of heart. Atherosclerosis, as a deposition of thrombotic plaques in the arteries, can cause ischaemia (reduced blood supply to tissues), which resulting in low oxygen supply known as hypoxia. Due to hypoxia, thrombotic plaques get deposited and cause tissue death in the layer of heart that ultimately cause myocardial infarction. Apart from this, some diseases and conditions are responsible for heart attack such as coronary artery disease (CAD), atrial fibrillation, cardiomyopathy, cardiomegaly, congestive heart failure, and angina pectoris. Among these, CAD is a major cause of heart attack. Symptoms related to heart condition include chest pain, pain in neck, and shortness of breath. According to World Health Organisation (WHO), heart attack caused around 17.9 million deaths globally.
Heart attack diagnosis includes different types of methods such as electrocardiogram (ECG), blood test, chest X-ray, echocardiogram, coronary catheterization or angiogram, and cardiac magnetic resonance imaging (cMRI). These methods can detect the conditions or chances of heart attack. Some of the common drug treatment for heart attack include aspirin, streptokinase, clopidogrel, rivaroxaban, nitro-glycerine, propranolol, captopril, and atorvastatin.
The report on the global heart attack diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Heart Attack Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Test Types (Electrocardiogram, Blood Tests [Troponin and Creatine Kinase MB Isoenzyme], and Echocardiogram) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Siemens Healthcare AG; Midmark Corporation; Schiller AG; Koninklijke Phillips N.V.; Hitachi healthcare; Toshiba International Corporation; F. Hoffmann-La Roche Ltd.; Abbott Laboratories Inc.; Bio-Rad Laboratories Inc.; Beckman Coulter, Inc.; AstraZeneca; Pfizer Inc., and Danaher Corporation |
Blood test segment is expected to grow at a rapid pace
Based on test types, the global heart attack diagnostics market is divided into electrocardiogram, blood tests, and echocardiogram. The blood tests segment is further subdivided into troponin and creatine kinase MB isoenzyme (CK-MB). The blood tests segment held a major market share in terms of revenue generation in 2020 and is expected to grow at rapid pace during the forecast period from 2021-2028. Wide uses of troponin blood test for detection of heart disease across the globe is projected to boost the blood test segment.
Asia Pacific is projected to accounts for a key share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in terms of revenue generation in 2020 and is projected to represent a key market share in the coming years. The regional market growth can be attributed to rising awareness and health expenditure on heart disease, desk-bound lifestyle, and adoption of advanced technology. However, Asia Pacific is projected to register a robust CAGR during the forecast period due to high incidence rate of heart disease, rising healthcare expenditure for cardiovascular diseases, and high aging populace in the region.
Some of the key players in the market are Siemens Healthcare AG; Midmark Corporation; Schiller AG; Koninklijke Phillips N.V.; Hitachi healthcare; Toshiba International Corporation; F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Bio-Rad Laboratories Inc; Beckman Coulter, Inc.; AstraZeneca; Pfizer Inc., and Danaher Corporation. Many of these key players are actively investing in research & development to develop new technologies and also actively engaged in various market strategies. Some of the key strategies adopted by players are product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe.
In May 2019, Abbott introduced a new technology for implantable cardiac monitor (ICM), which offered to observe cardiac pulse. In August 2015, Schiller AG developed CARDIOVIT FT-1 that proved to be useful for continuous monitoring of heart beat.
Some of the key players in the market are Siemens Healthcare AG; Midmark Corporation; Schiller AG; Koninklijke Phillips N.V.; Hitachi healthcare; Toshiba International Corporation; F. Hoffmann-La Roche Ltd; Abbott Laboratories Inc.; Bio-Rad Laboratories Inc; Beckman Coulter, Inc.; AstraZeneca; Pfizer Inc., and Danaher Corporation. Many of these key players are actively investing in research & development to develop new technologies and also actively engaged in various market strategies. Some of the key strategies adopted by players are product launches, mergers, partnerships, acquisitions, and expansion of production units to enhance their market position and expand their consumer base across the globe.
In May 2019, Abbott introduced a new technology for implantable cardiac monitor (ICM), which offered to observe cardiac pulse. In August 2015, Schiller AG developed CARDIOVIT FT-1 that proved to be useful for continuous monitoring of heart beat.
Some other reports from this category!